Drug Trial Radar · NCT03056755
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
383
Actual
Start
Aug 29, 2017
Primary completion
Jun 14, 2021
Study completion Nov 12, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive, HER2-negative aBC harboring PIK3CA mutation(s) in the tumor, whose disease had progressed on or after prior treatments.
Conditions
- Breast Cancer
Interventions
AlpelisibDrug
300 mg of alpelisib film-coated tablets administered orally once daily
FulvestrantDrug
500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
LetrozoleDrug
2.5 mg of letrozole film-coated tablets administered orally once daily
GoserelinDrug
3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
LeuprolideDrug
7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 MonthsTime frame: At 6 months
Locations
94 sites in 19 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Clinic Arizona
Phoenix, Arizona
Kaiser Permanente Medical Group
Anaheim, California
Beverly Hills Cancer Center
Beverly Hills, California
University of Calif Irvine Med Cntr
Irvine, California
Kaiser Permanent Southern Californi
San Diego, California
UCSF
San Francisco, California
Yale University Yale Cancer Center
New Haven, Connecticut
Advent Health Cancer Institute
Orlando, Florida
University of Kansas Cancer Center
Kansas City, Kansas
University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky
Mercy Medical Center
Baltimore, Maryland
Greater Baltimore Med Center Cancer Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Lahey Clinic
Burlington, Massachusetts
Josephine Ford Cancer Center
Detroit, Michigan
St Vincent Frontier Cancer Center
Billings, Montana
New Mexico Cancer Care Alliance
Albuquerque, New Mexico
Memorial Sloane Ketterin Cancer Ctr
New York, New York
Uni Hosp of Cleveland Cancer Center
Cleveland, Ohio
Texas Oncology
Dallas, Texas
Cancer Care Centers of South Texas HOAST
San Antonio, Texas
UT Health San Antonio
San Antonio, Texas
Virginia Oncology Associates
Norfolk, Virginia
Northwest Medical Specialists
Tacoma, Washington
Novartis Investigative Site
La Rioja, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Sante Fe, Argentina
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Kitchener, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Temuco, Araucania, Chile
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.